Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 3:45 PM
Ignite Modification Date: 2025-12-24 @ 3:45 PM
NCT ID: NCT01208792
Eligibility Criteria: Inclusion Criteria: age over 18 * for PAH patients: pre-capillary PAH evidenced by right-heart catheterization * no associated systemic disease for idiopathic PAH patients * for HIV patients, HIV1 infection confirmed by ELISA and western blot * for patients with porto pulmonary hypertension: evidence by endoscopy of esophageal varices, confirmation of hepatic venous pressure gradient over 5 mmHg by catheterization of the hepatic veins * for patients with congenital heart defect: evidence by imaging of atrial or ventricular septal defect, or patent ductus arterious and confirmed by heart catheterization * patients with SSc will fulfill the American College of Rheumatology (ACR) and the LEROY and MEDSGER criteria * patients with MCTD will fulfill the criteria for MCTD * patients with SLE will fulfill the updated and revised ACR criteria * patients with Sjögren's syndrome will fulfill the American-European consensus group criteria * patients with chronic thromboembolic pulmonary hypertension: Lung scintiscan showing segmental mismatched perfusion defects and confirmation by angiography of the occlusion and the chance of success of endarterectomy according to the location of disease * Signed written informed consent * Patients with health insurance Exclusion Criteria: * age under 18 * pregnant women * absence of written informed consent * associated malignant tumor
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Study: NCT01208792
Study Brief:
Protocol Section: NCT01208792